Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip et autres
0 citationsClinical Cancer Research
Ikbel Achour
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
91Publications signalées
1374Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentRenal Diseases and GlomerulopathiesRenal and related cancersMonoclonal and Polyclonal Antibodies Research
Publications récentes
Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.